Market Research Logo

US Market Report for Orthopedic Hyaluronic Acid Viscosupplementation 2017 - MedCore

US Market Report for Orthopedic Hyaluronic Acid Viscosupplementation 2017 - MedCore

Osteoarthritis, which is a condition marked by the degeneration of bone joints and cartilage, affected approximately 40 million people in the United States in 2016. Patients who suffer from osteoarthritis experience acute joint pain, tenderness, stiffness, creaking, locking of the joints and inflammation. These symptoms are caused by the degeneration of joint cartilage, subchondral bone and synovial fluid, specifically the polysaccharide hyaluronate. Cartilage and synovial fluid are important for absorbing stress and cushioning joints during normal activity. Progressive deterioration of cartilage and an overactive immune response may also lead to muscle atrophy and chronic disability.

General Report Contents

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions
Hyaluronic acid products involve one-, two-, three- or five-dose cycles, with the actual number of doses taken often being less than a full treatment. The growth of single-injection products over three- and five-injection products has been the most significant trend in the market. The single-injection has, to some extent, cannibalized other injection types; the convenience of the single-injection procedure has aided market penetration. The introduction of a two injection product in 2016 will further squeeze market share from the three- and five-injection products. Furthermore, viscosupplementation is beginning to be an expected treatment before joint replacement; this will drive unit sales growth.

As of 2016, both the single-injection and triple-injection markets were approximately the same in terms of market value, with the triple-injection being a little larger. While the three-injection market continues its positive growth, the collective hyaluronic acid viscosupplementation market is shifting to single-injection. The single-injection market is expected to become the largest segment of the HA market in the next couple of years because due to ease-of-use.


EXECUTIVE SUMMARY
U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
1.1 RESEARCH SCOPE
1.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
2.1 BASIC ANATOMY
2.1.1 Osteology and Musculoskeletal System
2.2 DISEASE PATHOLOGY AND DISORDERS
2.2.1 General Diagnostic
2.2.2 Osteoporosis
2.2.3 Osteoarthritis
2.2.4 Indication for Bone Graft Procedure
2.2.5 Indication for Cartilage Repair
2.2.6 Degenerative Disc Disease
2.3 PATIENT DEMOGRAPHICS
2.3.1 General Statistics
PRODUCT ASSESSMENT
3.1 PRODUCT PORTFOLIOS
3.1.1 Hyaluronic Acid Viscosupplementation
3.2 REGULATORY ISSUES AND RECALLS
3.2.1 Hyaluronic Acid Viscosupplementation
3.3 CLINICAL TRIALS
3.3.1 Hyaluronic Acid Viscosupplementation
ORTHOPEDIC HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
4.1 INTRODUCTION
4.1.1 Benefits of Viscosupplementation
4.1.2 Synovial Fluid
4.1.3 Product Types
4.1.3.1 Single-Injection Products
4.1.3.2 Two-Injection Cycle Products
4.1.3.3 Three-Injection Cycle Products
4.1.3.4 Three/Five-Injection Cycle Products
4.1.4 Reimbursement
4.2 MARKET OVERVIEW
4.3 MARKET ANALYSIS AND FORECAST
4.3.1 Total Hyaluronic Acid Viscosupplementation Market
4.3.1.1 Single-Injection Hyaluronic Acid Viscosupplementation Market
4.3.1.2 Three-Injection Hyaluronic Acid Viscosupplementation Market
4.3.1.3 Five-Injection Hyaluronic Acid Viscosupplementation Market
4.4 DRIVERS AND LIMITERS
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
APPENDIX II: COMPANY PRESS RELEASES
List of Charts
Chart 1 1: Orthopedic Biomaterials Market by Segment, U.S., 2013 – 2023
Chart 1 2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023
Chart 4 1: Orthopedic Hyaluronic Acid Viscosupplementation Market by Segment, U.S., 2013 – 2023
Chart 4 2: Orthopedic Hyaluronic Acid Viscosupplementation Market Breakdown, U.S., 2016
Chart 4 3: Orthopedic Hyaluronic Acid Viscosupplementation Market Breakdown, U.S., 2023
Chart 4 4: Total Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Chart 4 5: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Chart 4 6: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Chart 4 7: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Chart 4 8: Leading Competitors, Orthopedic Hyaluronic Acid Viscosupplementation Market, U.S., 2016
List of Figures
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (1 of 2)
Figure 1 2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (2 of 2)
Figure 1 3: Companies Researched in this Report, U.S., 2016
Figure 1 4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2)
Figure 1 5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2)
Figure 1 6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2013 – 2016
Figure 1 7: Orthopedic Biomaterials Markets Covered, U.S., 2016 (1 of 2)
Figure 1 8: Orthopedic Biomaterials Markets Covered, U.S., 2016 (2 of 2)
Figure 1 9: Orthopedic Biomaterials Markets Covered, U.S., 2016(1 of 3)
Figure 3 1: Hyaluronic Acid Viscosupplementationby Products by Company
Figure 3 2: Class 3 Device Recall Euflexxa (1 sodium hyaluronate)
Figure 3 3: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX)
Figure 3 4: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA)
Figure 3 5: Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis
Figure 3 6: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401)
Figure 3 7: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection
Figure 3 8: Platelet-rich Plasma vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology (PRP)
Figure 3 9: Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
Figure 3 10: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee
Figure 4 1: Orthopedic Hyaluronic Acid Viscosupplementation Market by Segment, U.S., 2013 – 2023 (US$M)
Figure 4 2: Total Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Figure 4 3: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Figure 4 4: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Figure 4 5: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2013 – 2023
Figure 4 6: Drivers and Limiters, Orthopedic Hyaluronic Acid Viscosupplementation Market, U.S., 2016
Figure 4 7: Leading Competitors, Orthopedic Hyaluronic Acid Viscosupplementation Market, U.S., 2016
Figure 6 1: Press Release Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report